ABSTRACT
【Objective】 To develop a new approach for the preparation of 0.7~0.8 hematocrit concentrated washed red blood cells(RBCs) for fetal anemia in utero transfusion and apply it in clinical. 【Methods】 The erythrocyte suspension and frozen stored erythrocytes within expiry date in Guangzhou Blood Center from March 2020 to February 2021 were taken to prepare concentrated washed RBCs. According to the derivation formula, corresponding weight of RBC preservation solution was added to obtain 0.7~0.8 hematocrit concentrated washed RBCs. Routine blood test data were statistically analyzed by single-sample t test, and P<0.05 was considered statistically significant. Qualified Rh-negative/ O-type 0.7~0.8 hematocrit concentrated RBCs within expiry date were used in clinical intrauterine blood transfusion. 【Results】 The hematocrit of concentrated washing RBCs prepared by the new approach could reach 0.7~0.8. The RBCs count (8.389 ±0.808)×1 012/ L and hemoglobin content(233.730±15.498)g/L were higher while the erythrocyte count (0.732±0.469)×109 /L and platelets count(26.000±26.276)×109/L were lower than the normal values of adults. The mean erythrocyte volume(fL), hemoglobin content(pg) and concentration(g/L )were 88.123±6.359, 30.004±2.809 and 339.980±11.865, respectively, which were normal values of adults. Fetal anemia was significantly improved and the prognosis was good after intrauterine blood transfusion. 【Conclusion】 The 0.7~0.8 hematocrit concentrated washed RBCs prepared by the new approach is consistent with the special blood requirements during fetal anaemia transfusion, meets the clinical treatment standards, and can be applied in clinical.
ABSTRACT
El teratoma sacrococcígeo es una enfermedad rara en el feto, pero con alta mortalidad perinatal debido al secuestro de flujo sanguíneo y consiguiente desarrollo de anemia fetal severa. Presentamos el caso de una gestante de 27 semanas referida a nuestro servicio para manejo prenatal de un feto con teratoma sacrococcígeo gigante, que desarrolló anemia fetal severa y fue sometido a una transfusión intrauterina intravascular, la cual pudo prolongar el embarazo y mejorar los resultados perinatales.
Sacrococcygeal teratoma is a rare fetal disease but with high perinatal mortality due to sequestration of blood flow and consequent development of severe fetal anemia. We present the case of a 27 weeks pregnant woman referred to our service for prenatal management of a fetus with giant sacrococcygeal teratoma and severe anemia and who was subjected to intrauterine intravascular transfusion that could permit prolongation of the pregnancy and improve perinatal results.
ABSTRACT
Objetivo: evaluar los resultados perinatales de las pacientes isoinmunizadas sometidas a transfusión fetal intrauterina en el Instituto Fernandes Figueira (Río de Janeiro, Brasil). Materiales y métodos: estudio descriptivo retrospectivo, que incluyó a mujeres que requirieron transfusión fetal intrauterina entre 1996 y 2006. Se analizaron la historia perinatal, los datos de la asistencia prenatal durante la gestación actual y los resultados perinatales. Resultados: a un total de 85 madres isoinmunizadas, 90 gestaciones y 94 fetos (4 gestaciones gemelares) se les hicieron 316 transfusiones intrauterinas. Todas las 90 gestaciones exhibían anticuerpos anti-Rh(D). Doce fetos (12,8) demostraban hidropesía en la primera transfusión y cinco (5,3%) tenían ascitis. Ocurrieron diez óbitos perinatales (4 óbitos fetales y 6 óbitos neonatales), totalizando una sobrevida de 89,4%. Fetos sin hidropesía tuvieron una sobrevida de 92,2% y fetos que presentaron hidropesía tuvieron un peor pronóstico, con sobrevida de 76,5%. Conclusiones: los resultados descritos confirman la eficacia y seguridad de la transfusión fetal intrauterina para el tratamiento de la anemia hemolítica inmune, realizada en centros de referencia para enfermedades perinatales.
Objective: evaluating the perinatal results of isoimmunised pregnancies submitted to intrauterine foetal transfusion at the Fernandes Figueira Institute (Rio de Janeiro, Brazil). Patients and methods: this was a retrospective descriptive review of the charts of isoimmunised pregnant women submitted to intrauterine foetal transfusion from 1996 to 2006. Perinatal history, antenatal assistance at the index pregnancy and perinatal outcomes were assessed. Results: 316 intra-uterine transfusions were given to 85 pregnant women (to correct foetal anaemia), 90 pregnancies and 94 foetuses(4 twin pregnancies). All 90 pregnancies had the anti-Rh(D) antibody. Twelve foetuses (12.8%) were hydropic at the first intrauterine transfusion and 5 (5.3% percent) presented ascitis. Survival rate was 89.4%, with 4 foetal deaths and 6 neonatal deaths. However, perinatal survival was 92.2% for non-hydropic foetuses and 76.5% for hydropic ones. Conclusions: these results confirmed the safety and efficacy of intrauterine transfusion when treating immune haemolytic anaemia if these procedures are performed in reference units for perinatal assistance when high-risk conditions are involved.
Objetivo: avaliar os resultados perinatais de gestantes isoimunizadas submetidas à transfusão intra-uterina no Instituto Fernandes Figueira (Rio de Janeiro, Brasil). Material e métodos: estudodescritivo,retrospectivo,oqualincluiugestantessubmetidasàtransfusão intra-uterina para correção da anemia hemolítica fetal entre 1996 e 2006. Foi analisado o histórico perinatal, os dados referentes à assistência pré-natal durante a gestação e os resultados perinatais. Resultados: 85 mulheres foram submetidas à transfusão intra-uterina, totalizando 90 gestações, 94 fetos (4 gestações gemelares) e 316 transfusões. Todas as gestantes tinham anticorpos anti-Rh(D). Doze fetos (12,8%) estavam hidrópicos quando da primeira transfusão e 5 (5,3%) tinham ascite isolada. Houve dez óbitos perinatais (4 óbitos fetais e 6 neomortos), totalizando uma sobrevida de 89,4%. Fetos sem hidropisia tiveram sobrevida de 92,2%, porémfetoshidrópicosapresentaramumpiorprognóstico, com sobrevida de 76,5%. Conclusões: os resultados descritos confirmam a eficácia e a segurança da transfusão intra-uterina para o tratamento da anemia hemolítica fetal quando realizadas em uma unidade de referência para a assistência perinatal.